Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Finished Goods (2019 - 2026)

Aytu Biopharma has reported Finished Goods over the past 7 years, most recently at $5.6 million for Q4 2025.

  • Quarterly Finished Goods fell 24.81% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 24.81% year-over-year, with the annual reading at $8.9 million for FY2025, 45.33% up from the prior year.
  • Finished Goods was $5.6 million for Q4 2025 at Aytu Biopharma, down from $7.9 million in the prior quarter.
  • Over five years, Finished Goods peaked at $12.0 million in Q4 2021 and troughed at $5.6 million in Q4 2025.
  • The 5-year median for Finished Goods is $8.4 million (2022), against an average of $8.3 million.
  • Year-over-year, Finished Goods skyrocketed 99.93% in 2021 and then crashed 32.89% in 2022.
  • A 5-year view of Finished Goods shows it stood at $12.0 million in 2021, then crashed by 30.08% to $8.4 million in 2022, then rose by 3.73% to $8.7 million in 2023, then dropped by 13.66% to $7.5 million in 2024, then decreased by 24.81% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Finished Goods are $5.6 million (Q4 2025), $7.9 million (Q3 2025), and $8.9 million (Q2 2025).